K T Murphy1, H Bundgaard, T Clausen. 1. Institute of Physiology and Biophysics, University of Aarhus, Arhus, Denmark. km@fi.au.dk
Abstract
BACKGROUND AND PURPOSE: In cardiac muscle, BRL 37344, a selective beta3-adrenoceptor agonist, activates the Na+, K+ -pump via NO signalling. This study investigated whether BRL 37344 also activates the Na+, K+ -pump via beta3-adrenoceptors in skeletal muscle. EXPERIMENTAL APPROACH: Isolated rat soleus muscles were incubated between 1 and 60 min in buffer. Intracellular Na+, K+ content and Na+, K+ -pump activity were measured using flame photometry and ouabain-suppressible 86Rb+ uptake, respectively. Additional muscles were mounted on force transducers and stimulated (60 Hz for 2 s) every 10 min. KEY RESULTS: BRL 37344 (10(-8) -10(-5) M) induced a concentration- and time-dependent reduction in intracellular Na+, and increased ouabain-suppressible 86Rb+ uptake by up to 112%. BRL 37344-induced reductions in intracellular Na+ were blocked by the beta1/beta2-adrenoceptor antagonist, nadolol (10(-7) M), and the beta2-adrenoceptor antagonist, ICI 118,551 (10(-7) -10(-5) M), but not by beta3- or beta1-adrenoceptor antagonists, SR 59230A (10(-7) M) and CGP 20712A (10(-7) -10(-5) M), respectively. Another beta3-adrenoceptor agonist, CL 316,243, did not alter intracellular Na+. BRL 37344-induced reductions in intracellular Na+ were not blocked by L-NAME, an NOS inhibitor, or ODQ, a guanylyl cyclase inhibitor. The NO donors, SNP and SNAP, did not alter intracellular Na+. BRL 37344 rapidly recovered force in muscles depressed by high [K+]o, an effect that was blocked by nadolol, but not L-NAME. CONCLUSIONS AND IMPLICATIONS: In rat soleus muscle, the beta3-adrenoceptor agonist BRL 37344 stimulated the Na+, K+ -pump via beta2-adrenoceptors. A more selective beta3-adrenoceptor agonist did not affect Na+, K+ homeostasis in skeletal muscle. NO did not seem to mediate Na+, K+ -pump stimulation in skeletal muscle.
BACKGROUND AND PURPOSE: In cardiac muscle, BRL 37344, a selective beta3-adrenoceptor agonist, activates the Na+, K+ -pump via NO signalling. This study investigated whether BRL 37344 also activates the Na+, K+ -pump via beta3-adrenoceptors in skeletal muscle. EXPERIMENTAL APPROACH: Isolated rat soleus muscles were incubated between 1 and 60 min in buffer. Intracellular Na+, K+ content and Na+, K+ -pump activity were measured using flame photometry and ouabain-suppressible 86Rb+ uptake, respectively. Additional muscles were mounted on force transducers and stimulated (60 Hz for 2 s) every 10 min. KEY RESULTS:BRL 37344 (10(-8) -10(-5) M) induced a concentration- and time-dependent reduction in intracellular Na+, and increased ouabain-suppressible 86Rb+ uptake by up to 112%. BRL 37344-induced reductions in intracellular Na+ were blocked by the beta1/beta2-adrenoceptor antagonist, nadolol (10(-7) M), and the beta2-adrenoceptor antagonist, ICI 118,551 (10(-7) -10(-5) M), but not by beta3- or beta1-adrenoceptor antagonists, SR 59230A (10(-7) M) and CGP 20712A (10(-7) -10(-5) M), respectively. Another beta3-adrenoceptor agonist, CL 316,243, did not alter intracellular Na+. BRL 37344-induced reductions in intracellular Na+ were not blocked by L-NAME, an NOS inhibitor, or ODQ, a guanylyl cyclase inhibitor. The NO donors, SNP and SNAP, did not alter intracellular Na+. BRL 37344 rapidly recovered force in muscles depressed by high [K+]o, an effect that was blocked by nadolol, but not L-NAME. CONCLUSIONS AND IMPLICATIONS: In rat soleus muscle, the beta3-adrenoceptor agonist BRL 37344 stimulated the Na+, K+ -pump via beta2-adrenoceptors. A more selective beta3-adrenoceptor agonist did not affect Na+, K+ homeostasis in skeletal muscle. NO did not seem to mediate Na+, K+ -pump stimulation in skeletal muscle.
Authors: Lan Zhou; Arthur L Burnett; Paul L Huang; Lewis C Becker; Periannan Kuppusamy; David A Kass; J Kevin Donahue; David Proud; James S K Sham; Ted M Dawson; Kai Y Xu Journal: Biochem Biophys Res Commun Date: 2002-06-28 Impact factor: 3.575
Authors: Lili A Barouch; Robert W Harrison; Michel W Skaf; Gisele O Rosas; Thomas P Cappola; Zoulficar A Kobeissi; Ion A Hobai; Christopher A Lemmon; Arthur L Burnett; Brian O'Rourke; E Rene Rodriguez; Paul L Huang; João A C Lima; Dan E Berkowitz; Joshua M Hare Journal: Nature Date: 2002-03-21 Impact factor: 49.962
Authors: P D Chamberlain; K H Jennings; F Paul; J Cordell; A Berry; S D Holmes; J Park; J Chambers; M V Sennitt; M J Stock; M A Cawthorne; P W Young; G J Murphy Journal: Int J Obes Relat Metab Disord Date: 1999-10
Authors: Robert A Ngala; Jacqueline F O'Dowd; Claire J Stocker; Michael A Cawthorne; Jonathan R S Arch Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2013-04-06 Impact factor: 3.000
Authors: Nicholas A Ratamess; Jill A Bush; Jie Kang; William J Kraemer; Sidney J Stohs; Vincenzo G Nocera; Megan D Leise; Keith B Diamond; Avery D Faigenbaum Journal: J Int Soc Sports Nutr Date: 2015-09-17 Impact factor: 5.150